March 20th 2024
"The ProVee System has the potential to be a first-line interventional therapy for BPH that can be safely and reliably performed in the office setting," says Steven A. Kaplan, MD.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Dr. Elterman weighs in on the growing number of BPH treatments available
September 16th 2021“My patient selection process for BPH treatments can be a little bit cumbersome and take time, but that's really because for the first time ever, we have so many different options available to men,” says Dean Elterman, MD, MSc, FRCSC.
Dr. Chughtai discusses advantages of iTind system for BPH-related LUTS
September 14th 2021“What's novel about the iTind system is [that] it's one of the first treatments that [can] be deployed through a flexible cystoscope, as well as the fact that there is no permanent energy or permanent foreign body that's left within the prosthetic urethra,” says Bilal Chughtai, MD.
Large retrospective study identifies racial disparity in surgical management for BPH
August 18th 2021A logistic regression analysis controlling for other major comorbidities, patient age, insurance status, and type of medical therapy found that Black patients were almost 40% less likely than White patients to undergo surgery for BPH.
Prostatic urethral lift gaining on TURP as treatment choice for benign prostatic enlargement/LUTS
August 1st 2021“Urologists tend to be early adopters of new technology. That said, how fast adoption of prostatic urethral lift has been in the urologic community was really impressive,” says Jonathan Shoag, MD.
TURP reimbursement denied due to misinterpretation of parenthetical attached to code
July 8th 2021"Depending on the age of the surgeon, one may be surprised to hear that it was common to perform a vasectomy routinely on patients undergoing a TURP procedure," write Jonathan Rubenstein, MD, and Mark Painter.
Is it appropriate to bill 51700 for urinary retention 2 weeks after TURP?
March 24th 2021"Placing a catheter to irrigate obstructing blood clots (CPT 51700) is specifically included in the payment for the TURP if this complication is managed outside of an operating room," write Jonathan Rubenstein, MD, and Mark Painter.